A carregar...
First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects
AIMS: Human genetic, tissue expression, proteomics, transcriptomics and nonclinical studies implicate tumour necrosis factor α‐like ligand 1A (TL1A) as a novel target in inflammatory bowel disease (IBD). PF‐06480605, a fully human immunoglobulin G1 monoclonal antibody, targets TL1A. This first‐in‐hu...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7098865/ https://ncbi.nlm.nih.gov/pubmed/31758576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14187 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|